M-CSF-specific monoclonal antibody and uses thereof

Details for Australian Patent Application No. 2005205533 (hide)

Owner Xoma Technology Ltd. Novartis Vaccines and Diagnostics, Inc.

Inventors Long, Li; Horwitz, Arnold H.; Liu, Cheng; Koths, Kirston; Calderon-Cacia, Maria; Harrowe, Gregory Martin; Zimmerman, Deborah Lee; Kavanaugh, William Michael

Agent FB Rice

Pub. Number AU-B-2005205533

PCT Pub. Number WO2005/068503

Priority 60/535,181 07.01.04 US; 60/576,417 02.06.04 US

Filing date 6 January 2005

Wipo publication date 28 July 2005

Acceptance publication date 22 March 2012

International Classifications

C07K 16/00 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

17 August 2006 PCT application entered the National Phase

  PCT publication WO2005/068503 Priority application(s): WO2005/068503

24 April 2008 Assignment before Grant

  Chiron Corpoartion ; Xoma Technology Ltd. The application has been assigned to Xoma Technology Ltd.; Novartis Vaccines and Diagnostics, Inc.

22 March 2012 Application Accepted

  Published as AU-B-2005205533

19 July 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005205544-Radio network relocation

2005205531-Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders